Indolent Lymphomas

This book provides a comprehensive overview of current treatment strategies in indolent lymphomas, the clinical management of which continues to pose significant challenges for the general oncologist despite the tremendous progress in diagnosis, evaluation of risk factors, and molecular targeted approaches. Experts in the field from around the world describe the histomorphology in a clinically relevant manner, consider the role of risk factors in detail, and discuss the full spectrum of therapeutic approaches. Special emphasis is placed on the translation of molecular science into clinical care, and a disease-specific algorithm is proposed for each entity. The coverage encompasses follicular lymphoma, MALT, nodal marginal zone lymphoma, splenic marginal zone lymphoma, Waldenström’s macroglobulinemia, hairy cell leukemia, chronic lymphocytic leukemia, mycosis fungoides, large granular lymphocytic leukemia, and also mantle cell lymphoma. The book will be an excellent resource for experienced and inexperienced practitioners alike.

This first open access European CAR-T Handbook, co-promoted by the European Society for Blood and Marrow Transplantation (EBMT) and the European Hematology Association (EHA), covers several aspects of CAR-T cell treatments, including the underlying biology, indications, management of side-effects, access and manufacturing issues. This book, written by leading experts in the field to enhance readers’ knowledge and practice skills, provides an unparalleled overview of the CAR-T cell technology and its application in clinical care, to enhance readers’ knowledge and practice skills.

Hodgkin lymphoma and the many different subtypes of non-Hodgkin lymphoma (NHL) have different responses to treatment, so accurate diagnosis and a rational approach to management are essential. 'Fast Facts: Lymphoma' distills the most important aspects of the diagnosis and management of these complex disorders into a highly accessible well-illustrated summary of the key facts. This fully updated second edition provides: • a clear outline of the nature of lymphoma • the essentials of clinical presentation, biopsy and basic histology • the latest laboratory diagnostics, including immunophenotyping, cytogenetics and microarray technology • key aspects of staging and initial therapy • superbly illustrated overviews of the pathology, presentation, treatment and prognosis of each lymphoma subtype • new treatment options, including targeted biological therapies • a practical overview of supportive care for the complications of lymphoma Written by three experts in the field from the UK and USA, 'Fast Facts: Lymphoma' applies an international perspective to this challenging disease in a unique format within the context of clinical practice. It is a valuable resource for trainee doctors and specialist nurses working in the field of hemato-oncology. It will also be of interest to the inquiring patient or carer who wishes to know more about lymphoma. Contents: • Epidemiology • Cellular and molecular aspects • Presentation, biopsy and diagnostic laboratory techniques • Staging and general management principles • Aggressive B-cell lymphomas • Indolent B-cell lymphomas • T-cell and natural-killer cell lymphomas • Immunocompromised and HIV-positive patients • Hodgkin lymphoma • Treatment modalities • Supportive care

Lymphoma affects all ages. Advances in diagnostic cellular and molecular techniques coupled with new treatment options are improving patient outcomes. This third edition of our bestselling 'Fast Facts: Lymphoma' distills the most important aspects of diagnosis and management into an up-to-date and highly accessible well-illustrated overview that includes: • a clear outline of the nature of lymphoma • the essentials of clinical presentation, biopsy and histology • a synopsis of current laboratory diagnostics, including immunophenotyping, cytogenetics and microarray technology, and updated to include the latest molecular genetic techniques • key aspects of staging and initial therapy • clearly illustrated overviews of the pathology, presentation, treatment and prognosis of each lymphoma subtype • new treatment options, including targeted biological therapies and chimeric antigen receptor T cells (CAR T cells) • a practical overview of supportive care for the complications of lymphoma. Written by three lymphoma experts from the UK and USA, 'Fast Facts: Lymphoma' gives an interesting international perspective to this challenging disease. Its clarity and colorful format make it a valuable resource for senior health professionals seeking an accessible update in this area of hemato-oncology, trainee doctors and specialist nurses who are new to it, and individuals affected by lymphoma and seeking more information. Contents: • Epidemiology • Cellular and molecular aspects • Presentation, biopsy and diagnostic laboratory techniques • Staging and general management principles • Aggressive B-cell lymphomas • Indolent B-cell lymphomas • T-cell and natural-killer cell lymphomas • Immunocompromised and HIV-positive patients • Hodgkin lymphoma • Treatment modalities • Supportive care

Lymphomas form a heterogeneous group of diseases as regards aggressiveness, need of care and prognosis. In some disease types the treatment should be started without delay, whereas others may not need care at all.Adults with generalized lymphadenopathy, hepatosplenomegaly or an enlarged lymph node (> 2 cm) that does not decrease in size during a follow-up of one month should be referred for biopsy to a specialist centre with good pathology services. If a patient has prolonged symptoms after treatment of lymphoma, thorough investigations are indicated to rule out recurrence. Consider the possibility of late adverse effects of treatment (early menopause, hypothyroidism, cardiac disease, certain infections and secondary malignancies).

This issue of Emerging Cancer Therapeutics provides a comprehensive review for practitioners on the current status of lymphoma subtypes. Lymphoma includes: • Expert contributors from across the US and Canada • Multidisciplinary coverage and emphasis on emerging therapeutic options, cutting edge developments and clinical research with near-term potential in clinical management Series Description: Emerging Cancer Therapeutics is an invited review publication providing a thorough analysis of key clinical research related to cancer therapeutics, including a discussion and assessment of current evidence; current clinical best practice, and likely near future developments. There is an emphasis throughout on multidisciplinary approaches to the specialty, as well as on quality and outcomes analysis. Published three times a year, Emerging Cancer Therapeutics provides authoritative, thorough assessments of advances in therapeutics in all major areas of oncology, both solid and hematologic malignancies, with a focus on advances in medical and biological therapies with emerging clinical impact and encompassing new technologies with implications for management such as molecular imaging.